Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies
Abstract Introduction Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) are scarce. The OPUS/OrPHeUS studies enrolled patients with PAH newly initiating macitentan, including those with PAH associat...
Saved in:
| Main Authors: | Kelly M. Chin, Richard Channick, Nick H. Kim, Rose Ong, Stefano Turricchia, Nicolas Martin, Lada Mitchell, Vallerie V. McLaughlin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Cardiology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40119-024-00386-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
by: Richard Channick, MD, et al.
Published: (2025-02-01) -
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
by: Robert P. Frantz, et al.
Published: (2024-10-01) -
Development and validation of an LC-MS/MS method for the simultaneous estimation of tadalafil and macitentan in rat plasma: Greenness assessment and design of experiment approach
by: Sravanthi Gandu, et al.
Published: (2025-03-01) -
Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial
by: Mandana Kashaki, et al.
Published: (2025-01-01) -
Black Orpheus
by: Hlonipha Mokoena
Published: (2022-06-01)